



**Mereo BioPharma Group plc**  
(“Mereo” or the “Company” or the “Group”)

**Mereo BioPharma to Present at Cantor Global Healthcare Conference on 26 September 2017**

**London, 18 September 2017** – Mereo BioPharma Group plc (AIM: MPH), a clinical stage, UK-based, biopharmaceutical company focused on rare and specialty diseases, is pleased to announce that Denise Scots-Knight, Chief Executive Officer of Mereo will present an overview of the business at the Cantor Global Healthcare Conference 2017, to be held 25-27 September 2017 in New York.

**Mereo BioPharma Presentation Details**

Date: Tuesday, 26 September 2017

Time: 8:35-9:05 AM ET (1:35-2:05 PM BST)

Location: InterContinental New York Barclay Hotel, 111 E 48th St, New York, NY 10017, USA

Track & Room: Grand Ballroom 2 - Track 5

**For Further Enquiries:**

***Mereo BioPharma Group plc***

Denise Scots-Knight, Chief Executive Officer  
Richard Jones, Chief Financial Officer

**+44 (0)333 023 7319**

***Nominated Adviser and Joint Broker***  
***Cantor Fitzgerald Europe***

Phil Davies  
Will Goode

**+44 (0)20 7894 7000**

***Joint Broker***  
***RBC Capital Markets***

Rupert Walford  
Laura White

**+44 (0)20 7653 4000**

***Public Relations Adviser to Mereo Biopharma***  
***FTI Consulting***

Ben Atwell  
Simon Conway  
Brett Pollard

**+44 (0)20 3727 1000**

***US Public Relations Advisor to Mereo Biopharma***  
***Burns McClellan***

Lisa Burns  
Steven Klass

**+01 (0) 212 213 0006**

**About Mereo**

Mereo BioPharma is an innovative biopharma company established to address the R&D and financial challenges faced by an increasing number of large pharma and biotech companies. Mereo focuses on developing and optimizing the value of novel medicines acquired from large pharma and biotech designed to address significant unmet medical needs in rare and specialty disease areas.

Mereo is comprised of a strong team with broad operational capabilities and the financial resources to conduct comprehensive clinical studies. The Company plans to build a rare and orphan commercial business combined with plans to partner where relevant.

Mereo's initial portfolio consists of three mid-late stage clinical assets that were acquired from Novartis in July 2015 each with proof of concept data in the indication that Mereo is now developing. BPS-804 is being developed for the prevention of fractures resulting from osteogenesis imperfecta (brittle bone disease); acumapimod (BCT-197), is being developed to treat inflammation in patients with an AECOPD; and BGS-649 is a once-weekly oral novel therapy that restores the patient's own testosterone in men with hypogonadotropic hypogonadism.

In H1 2016 the Company initiated a Phase 2 study with acumapimod and a Phase 2b study with BGS-649. Mereo recently announced commencement of the first potentially pivotal Phase 2b trial for BPS-804 and completion of enrolment of both the acumapimod Phase 2 study and the BGS-649 Phase 2b study. Additional product opportunities, from a range of large pharmaceutical and biotechnology companies, are under active evaluation and these are focussed on orphan and rare diseases.